STRATEGIC SCIENTIFIC ADVISORY · CASE STUDIES
SELECTED WORK
A proposed active with encouraging in vitro data was assessed against the causal pathway it claimed to address. The mechanism was plausible but the evidence was correlative; the recommendation was a defined confirmatory study before licensing.
A validated technology with no route to market was sequenced into a commercial programme — evidence package, regulatory pathway, and channel strategy developed together rather than in series.
A formulation concept was rebuilt around delivery and stability constraints identified early, avoiding a late-stage reformulation that would have reset the clinical timeline.
A research portfolio was reordered so that the experiments capable of disproving the central hypothesis were run first, rather than last.
A product established in one region was prepared for regulated markets abroad, with claim sets and dossiers adapted to each jurisdiction's evidentiary standard.
Patent strategy and experimental design were aligned so that the data generated actually supported the claims being pursued.
SELECTIVE COLLABORATIONS
Documented outcomes rather than assertions — released as confidentiality allows.
Enquire about an advisory engagement